Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Oxycodone
Drug ID BADD_D01645
Description Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917.[A178696] It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.[L6460]
Indications and Usage Oxycodone is indicated for the treatment of moderate to severe pain.[Label] There is also an extended release formulation indicated for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label]
Marketing Status approved; illicit; investigational
ATC Code N02AA05
DrugBank ID DB00497
KEGG ID D05312
MeSH ID D010098
PubChem ID 5284603
TTD Drug ID D07WPQ
NDC Product Code 71335-0981; 67651-0304; 67651-0305; 67651-0306; 24510-140; 71335-1080; 0904-6966; 24510-130; 65162-048; 67877-625; 71335-0677; 65162-050; 0904-7180; 65162-047; 72162-1812; 67877-623; 67651-0302; 65162-049; 67651-0303; 65162-051; 24510-110; 24510-115; 71335-1023; 24510-120; 72162-1811
UNII CD35PMG570
Synonyms Oxycodone | Dihydrone | Oxycone | Dihydrohydroxycodeinone | Oxycodeinon | Eucodal | Theocodin | Oxycodone Hydrochloride | Oxycontin | Pancodine | Dinarkon | Oxiconum
Chemical Information
Molecular Formula C18H21NO4
CAS Registry Number 76-42-6
SMILES CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)OC)O4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hepatic cancer recurrent16.07.02.006; 09.04.02.0110.000021%Not Available
Poor feeding infant18.04.06.006; 14.03.02.0220.000021%Not Available
Toxic leukoencephalopathy17.13.02.012; 12.03.01.0590.000259%Not Available
Disorganised speech17.02.08.017; 19.19.02.0050.000166%Not Available
Substance dependence19.07.06.0190.000031%Not Available
Mental fatigue19.21.02.012; 17.03.03.0060.000021%Not Available
Infantile back arching15.03.05.018; 18.04.01.0170.000021%Not Available
Allergic reaction to excipient10.01.01.035--Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000145%Not Available
Behaviour disorder19.01.01.0050.000207%Not Available
Congestive hepatopathy09.01.06.027; 02.05.04.0180.000031%Not Available
Drug effect less than expected08.06.01.036--Not Available
Drug use disorder19.07.06.0120.000207%Not Available
Foreign body embolism24.01.01.040; 12.02.05.0540.000021%Not Available
Foreign body reaction08.01.05.016; 23.03.15.0120.000041%Not Available
Inadequate analgesia12.02.20.006; 08.06.01.0400.002204%Not Available
Myocardial injury02.04.02.0460.000041%Not Available
Narcotic bowel syndrome07.02.05.0060.000041%Not Available
Near death experience19.10.05.007; 17.02.04.0230.000062%Not Available
Paranoid personality disorder19.05.05.0010.000021%Not Available
Paroxysmal sympathetic hyperactivity17.05.01.030; 12.01.10.0180.000052%Not Available
Precancerous condition08.03.04.010--Not Available
Reaction to excipient10.01.01.0420.000116%Not Available
Resorption bone increased15.02.03.021; 14.04.04.0200.000021%Not Available
Self-consciousness19.05.01.025--Not Available
Substance use disorder19.07.06.0200.000062%Not Available
Therapeutic product effect increased08.06.01.0530.000203%Not Available
Therapeutic product effect variable08.06.01.055--Not Available
The 16th Page    First    Pre   16    Total 16 Pages